AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02521025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous feeding pattern
Description: Continuous feeding
Study NCT03657537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketone infusion
Description: β-hydroxybutyrate is infused intravenously.
Study NCT03657537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline infusion
Description: saline is infused intravenously.
Study NCT02391116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib (Aliqopa, BAY80-6946)
Description: Participants assigned to receive copanlisib intravenous (IV) infusion at a dose of 60 mg as single agent on Days 1, 8, and 15 of 28-day treatment cycle. Copanlisib treatment was to be continued until disease progression (PD), unacceptable toxicity, or until another criterion was met for withdrawal from the study treatment
Study NCT01437384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E5501
Description: 20 mg oral dose of E5501; 240 mg once daily oral dose of sustained release verapamil; 400 mg oral dose of cyclosporine
Study NCT00502983 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interview
Description: Interview lasting approximately 50 minutes.
Study NCT02958813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMARA
Description: Morning and afternoon sessions begin with an icebreaker and/or poem to enhance ethnic and gender pride. IMARA's goals and motto are presented to emphasize strong mother-daughter relationships, foster sisterhood, build group cohesion, and increase motivation. Ground rules are reviewed, and each woman and girl signs the IMARA pact to confirm her commitment to the program. At the end of day 1, mothers and daughters receive homework for the week. Woven throughout IMARA is the impact of alcohol and drug use on risk behavior, including condom use while high.
Study NCT02958813 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: FUEL
Description: FUEL™ Health Promotion Control Group: mothers and daughters randomly assigned to FUEL™ will participate in separate 2-day workshops identical in length and intensity to IMARA. FUEL™ promotes healthy activities by encouraging good nutrition, exercise, and informed consumer behavior. Investigators will also insert the following sessions from Balance into FUEL: alcohol use, drug/marijuana use, nutrition, exercise, and violence to increase program length.
Study NCT01845558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wobenzym® plus
Study NCT01845558 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00812825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04171327
Description: PF-0417327 will be provided as an oral solution administered at doses of 1, 3, 10 and 30 mg. If an additional cohort is required, the dose selected will not exceed 100 mg. Solution will be administered once daily for 14 days.
Study NCT00812825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Oral doses of prednisolone (5, 10, and 20 mg) will be administered to the first three cohorts. The fourth cohort will receive between 1 and 20 mg to be determined after the third cohort completes dosing. If an additional cohort is required, the dose selected will not exceed 40 mg. Prednisolone tablets will be administered once daily for 14 days
Study NCT00812825 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets similar in appearance to prednisolone will be administered once daily for 14 days.
Study NCT00812825 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo Solution
Description: Placebo solution will be administered to those volunteers who are randomized to the placebo or prednisolone arms. This will be administered orally each day for 14 days.
Study NCT00937040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OROS MPH
Description: Optimal Patient Dose (18 mg-72 mg) once daily for 6 weeks
Study NCT00937040 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Optimal Patient Dose (placebo to match 18 mg - 72 mg) once daily for 6 weeks
Study NCT00937040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OROS MPH Tablets
Description: Optimal Patient Dose (18 mg-72 mg) once daily by mouth for 6 weeks
Study NCT04478513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4635
Description: During each treatment period subjects will receive a single dose of AZD4635 under fasting conditions.
Study NCT04478513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: Daily oral single doses of fluvoxamine are planned to be administered to healthy volunteers in Treatment Period 2.
Study NCT02498379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cu[64]-25%CANF-Comb
Description: Intravenous injection of 4-8 mCi of Cu\[64\]-25%CANF-Comb with PET-CT scans performed 1-4 hours, 5-10 hours, and 22-26 hours or 46-50 hours after injection.
Study NCT04733196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Essential oils
Description: Participants were asked to rinse with 15 ml mouthwash twice daily for 21 days.
Study NCT00812825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04171327 Tablet
Description: A single 10 mg dose of PF-04171327 tablet formulation will be administered orally to volunteers in Part 2 of this study.
Study NCT02261285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4538
Study NCT02947581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole and praziquantel
Description: Intervention - PZQ (50 mg/k/d, up to 3600 mg/d, for 15 days), as an add-on to ABZ treatment (15 mg/k/d, up to 800 mg/d for days 1-20, up to 1200 mg/d for days 21-30). In order to maintain the double blind nature of the trial, ABZ placebo will be administered to individuals over 53 kg of weight until completing the equivalent doses in the comparison group.
Study NCT02947581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole and praziquantel placebo
Description: PZQ placebo in similar doses, given during the initial 15 days of ABZ treatment at standard doses (15 mg/k/d up to 1200 mg/d for 30 days)
Study NCT01137123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adjuvant chemotherapy
Description: Docetaxel 75mg/m2 +Nedaplatin 75mg/m2,IV drip on day 1 of each 21 day cycle. Number of cycles: till unacceptable toxicity develops and no more than 4 cycles.
Study NCT00937040 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablets
Description: Optimal Patient Dose (placebo to match 18 mg - 72 mg) once daily by mouth for 6 weeks
Study NCT01137123 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard two field Lymphadenectomy
Description: Standard two field lymphadenectomy is standard mediastinal lymphadenectomy which defined by the International Association of esophageal disease(ISDE) of thoracic esophageal cancer.
Study NCT01137123 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard two field Lymphadenectomy
Description: Standard two field lymphadenectomy is standard mediastinal lymphadenectomy which defined by the International Association of esophageal disease(ISDE) of thoracic esophageal cancer.
Study NCT04733196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Essential oils in combination with chlorhexidine 0,12%
Description: Participants were asked to rinse with 15 ml mouthwash twice daily for 21 days.
Study NCT04733196 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo mouthwash
Description: Participants were asked to rinse with 15 ml mouthwash twice daily for 21 days.
Study NCT04733196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0,20 % in combination with aroma oils
Description: Participants were asked to rinse with 15 ml mouthwash twice daily for 21 days.
Study NCT04733196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prebiotic
Description: Participants were asked to rinse with 15 ml mouthwash twice daily for 21 days.
Study NCT04733196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide 0,8 %
Description: Participants were asked to rinse with 15 ml mouthwash twice daily for 21 days.
Study NCT01137123 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total two field Lymphadenectomy
Description: Total two field Lymphadenectomy is total mediastinal lymphadenectomy which defined by the International Association of esophageal disease(ISDE) of thoracic esophageal cancer.
Study NCT02781753 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Serum Albumin/interferon alpha2b
Description: Human Serum Albumin/interferon alpha2b fusion protein 300-1200 μg single dose S.C. at Day0
Study NCT02781753 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon 180 μg single dose S.C.
Description: Pegasys 180 mcg S.C. single dose on Day 0
Study NCT02704520 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: High resolution MRI scan
Description: MRI reporting of tumour but not mrTRG in the control arm = standard of care
Study NCT02704520 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: High resolution MRI scan
Description: MRI reporting of tumour but not mrTRG in the control arm = standard of care
Study NCT02704520 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: mrTRG assessment
Description: Watch and wait offered for good responders Consider further treatment for poor responders
Study NCT02622373 — intervention group
Intervention type: DEVICE
Intervention: PEA POD Infant Body Composition System
Description: The non-invasive device used in this study to measure a baby's body composition is a called a Pea Pod. The Pea Pod is a quick, safe, non-invasive and reliable bedside procedure used to measure changes in infant body composition.
Study NCT03358589 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: FDG-PET/CT
Description: Scans
Study NCT01734538 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Complete
Study NCT01734538 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Study NCT01931579 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: confocal endo-microscopy
Description: The intervention consists of the use of confocal endo-microscopy using the CELLVIZIO device and either the 1 mm CELLVIZIO miniprobe (ALVEOFLEX) or the 0.6 mm CELLVIZIO miniprobe (CHOLANGIOFLEX), during a navigational bronchoscopy procedure for the diagnostic of peripheral nodule. In this study, the navigational device - either radial endobronchial ultrasound (EBUS) or electromagnetic navigation (EMN) - will be moved to another location if the CELLVIZIO displays a non solid pattern, indicating that the nodule may not have been reached during the procedure. Three attempts of EBUS or EMN are allowed until the CELLVIZIO shows a solid pattern.
Study NCT00552773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclamen Europaeum
Description: Nasal spray 10% (V/V),one spray per nostril daily for 7 days.
Study NCT00552773 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclamen Europaeum
Description: Nasal spray 10% (V/V),one spray per nostril daily for 7 days.
Study NCT02638571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enhanced education on pulse use in complementary foods
Description: Enhanced Nutrition education with sessions and counseling by health extension workers
Study NCT00220961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone tablets - 45 mg/day
Study NCT00220961 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets similar to pioglitazone tablets - 1 tablet/day
Study NCT02215733 — intervention group
Intervention type: DRUG
Intervention: ARB
Description: other than telmisartan
Study NCT02638571 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: enhanced education on pulse use in complementary foods
Description: Enhanced Nutrition education with sessions and counseling by health extension workers
Study NCT04616573 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OMNI® Surgical System
Description: Ab-interno transluminal viscoelastic delivery and trabeculotomy performed with the OMNI Surgical System
Study NCT04616573 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iStent inject
Description: Trabecular meshwork implantation
Study NCT04463056 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elizaria®
Description: Induction cycle: 600 mg (2 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes once a week for 4 weeks. Maintenance therapy: 900 mg (3 vials of 30 mL, 10 mg/mL) intravenous infusion for 30 minutes in Week 5, followed by 900 mg every 14 days.
Study NCT02215733 — intervention group
Intervention type: DRUG
Intervention: ACEI
Study NCT02215733 — intervention group
Intervention type: DRUG
Intervention: Beta-blockers
Study NCT02215733 — intervention group
Intervention type: DRUG
Intervention: Diuretics
Study NCT02215733 — intervention group
Intervention type: DRUG
Intervention: Telmisartan
Study NCT00459303 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: aspherical intraocular lens
Description: implantation of aspherical intraocular lenses(AMO Tecnis Z9000)during cataract suregry (small cornea incision phacoemulsification, deliver with Monarch II device, in the bag implantation)
Study NCT00459303 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: spherical intraocular lens
Description: implantation of spherical intraocular lenses(Alcon SA60AT Acrysof)during cataract suregry (small cornea incision phacoemulsification, deliver with Monarch II device, in the bag implantation)
Study NCT04398693 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prebiotic
Description: It shall be a double-blinded, randomized, placebo-controlled crossover study and treatment with prebiotic for 4 weeks. After a washout period of 4 weeks, the study protocol will be repeated in the other arm. Participants will receive supplementary diet based on high-amylose cornstarch, which releases large amounts of SCFA (acetate and butyrate) in a sachet with a powder that must be dissolved in a glass of liquid to your choice, during 4 weeks (20 g 2x/day). Participants will undergo anthropometric, biochemistry and GUT microbiota assessment, before and after the end of the first phase of the crossover study. Later, when the inversion of the treatment groups occur all participants will also be subjected to the same procedures before and after the end of the second phase of the study.
Study NCT03018743 — intervention group
Intervention type: DRUG
Intervention: Dapoxetine
Description: Patients receive dapoxetine (taken 1-3 hours before sexual intercourse) 30mg as needed. A dose escalation to 60mg will be consented after 1 month in case of low efficacy. Patients will be re-evaluated 1, 3, 6, 12, and 24 months after initiating therapy regarding the treatment status and the reasons for treatment discontinuation in the case of discontinuation. If patients missed any visits, they will be contacted by telephone or mail to collect their treatment data.
Study NCT03091101 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scleral lens wearing keratoconics
Description: Cohort of keratoconics fitted with scleral lenses and monitored over 6 months
Study NCT05505253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alfacalcidol 0.0005 MG
Description: Alfacalcidol 0.5 mcg is given orally for 3 months, then vitamin D3 and vitamin D receptor levels are measured
Study NCT05505253 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drug is given orally for 3 months, then vitamin D3 and vitamin D receptor levels are measured
Study NCT02319733 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold
Description: Implantation of Bioresorbable vascular scaffold in vulnerable plaques
Study NCT02500563 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Amino acid based infant formula
Study NCT02500563 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed casein infant formula
Study NCT02500563 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mother's own breast milk
Study NCT00841516 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was given the same way as a subcutaneous (just under the skin) injection.
Study NCT00841516 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rBet v1-FV
Description: Placebo was given the same way as a subcutaneous (just under the skin) injection.
Study NCT01225913 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: fluticasone/salmeterol in all asthmatics
Description: budesonide 80ug/formoterol 4.5ug, 2 inhalations bid X 20-60 days or fluticasone 100ug/salmeterol 50ug, 1 inhalation bid X 20-60 days
Study NCT01225913 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: budesonide/formoterol or fluticasone/salmeterol in all asthmatics
Description: budesonide 160ug/formoterol 4.5ug, 2 inhalations bid or fluticasone 250ug/salmeterol 50ug, 1 inhalations bid
Study NCT00735644 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Japanese encephalitis vaccine
Description: 0.5 mL, Subcutaneous
Study NCT00735644 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Japanese encephalitis vaccine (Acambis)
Description: 0.5 mL, Subcutaneous
Study NCT00735644 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Hepatitis A vaccine
Description: 0.5 mL, Intramuscular
Study NCT03835936 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High frequency compression of the chest wall group
Description: The protocol in the high frequency compression of the chest wall group device consists of the Smart Vest® application, with a fixed frequency of 13 Hz and a time of 15 minutes. The selected mode will be the normal (fixed parameters) and the pressure of 4 units (12 cm H2O). The patient remains seated on his parents, and with a cotton garment between the vest and the skin of the patient to prevent skin lesions.
Study NCT03835936 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual maneuvers physiotherapy group
Description: 20 minutes of manual maneuvers physiotherapy based on prolonged slow expiration: passive technique of expiratory help applied to the baby through a slow thoracic-abdominal pressure that begins at the end of spontaneous expiration and continues to the residual volume. The physiotherapist through the cough provoked or stimulation of the trachea gets expectoration of sputum, to be able to assess its weight.
Study NCT03835936 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual maneuvers physiotherapy group
Description: 20 minutes of manual maneuvers physiotherapy based on prolonged slow expiration: passive technique of expiratory help applied to the baby through a slow thoracic-abdominal pressure that begins at the end of spontaneous expiration and continues to the residual volume. The physiotherapist through the cough provoked or stimulation of the trachea gets expectoration of sputum, to be able to assess its weight.
Study NCT01325649 — intervention group
Intervention type: PROCEDURE
Intervention: total mesorectal excision / long course radiochemotherapy
Description: long course 5-FU based radiochemotherapy before total mesorectal excision
Study NCT01325649 — intervention group
Intervention type: RADIATION
Intervention: long course 5-FU bases radiochemotherapy
Study NCT02587559 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: physical therapy
Description: application of manual therapy techniques to upper extremity along with therapeutic exercise procedures to the axioscapular and rotator cuff musculature
Study NCT04577313 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Self-Regulation Adherence Counseling
Description: Telephone-delivered counseling to focus on cognitive-behavioral skills to improve HIV treatment adherence.
Study NCT04096989 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine regimen-based lifestyle mobile health APP
Description: The Experimental group receives TCM regimen-based lifestyle mobile health application intervention.
Study NCT04096989 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Lifestyle mobile health APP
Description: Sham comparator group receives mobile health application, but there is no traditional Chinese medicine information.
Study NCT03214510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Given via thoracic epidural catheter or TAP block
Study NCT03214510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Given via thoracic epidural catheter
Study NCT03214510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone Hydrochloride
Description: Given via thoracic epidural catheter
Study NCT03214510 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implanted Medical Device
Description: Undergo placement of thoracic epidural catheter
Study NCT03214510 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implanted Medical Device
Description: Undergo placement of ultrasound-guided, four-quadrant transversus abdominus plane block
Study NCT03214510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine
Description: Given via TAP block
Study NCT03214510 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Ancillary studies